Chemotherapy
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity
EBioMedicine 2024 November [Link] Mégane Willems, Malik Hamaidia, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Lea Vilanova Mañá, Roxane Terres, Majeed Jamakhani, Sophie Deshayes, Yves Brostaux, Vincent Heinen, Renaud Louis, Bernard Duysinx, Didier Jean, Eric Wasielewski, Arnaud Scherpereel, Christophe Blanquart, Luc Willems Abstract Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively…
Read MoreSystemic Therapy Options for Peritoneal Mesothelioma
Journal of the Comprehensive Cancer Network 2024 October [Link] Tawee Tanvetyanon, George R Simon Abstract Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials…
Read MoreImmunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
International Journal of Molecular Sciences 2024 October 9 [Link] Lauren Chiec, Debora S Bruno Abstract Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual…
Read MorePhase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design
Cancers 2024 October 4 [Link] Giulia Maria Stella, Daniela Lisini, Paolo Pedrazzoli, Giulia Galli, Chandra Bortolotto, Giulio Melloni, Gioacchino D’Ambrosio, Catherine Klersy, Amelia Grosso, Francesca Paino, Stefano Tomaselli, Laura Saracino, Giulio Alessandri, Augusto Pessina, Elena Grignani, Vittorio Rosti, Angelo Guido Corsico, Patrizia Comoli, Francesco Agustoni Abstract Background and rationale. Pleural mesothelioma (PM) is a rare…
Read MoreThe Significance of the Morphological Appearance of Peritoneal Lesions on Imaging in Patients With Peritoneal Malignancies-A Report From Phase 1 of the PRECINCT Study
Journal of Surgical Oncology 2024 September 19 [Link] Aditi Bhatt, Pascal Rousset, Brendan J Moran, Mudaddal Kazi, Dario Baratti, Amine Souadka, Marcello Deraco, Paolo Sammartino, Armando Sardi, Olivier Glehen Abstract Peritoneal tumour dissemination is still considered as a terminal disease. For the last two decades, cytoreductive surgery (CRS) combined with intraoperative hyperthermic chemotherapy (HIPEC) has…
Read MorePerfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Journal of Surgical Oncology 2024 September 10 [Link] Claire Drigotas, Alexander W Loftus, John B Ammori, Luke D Rothermel, Richard S Hoehn Abstract Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to…
Read MoreDrug sensitivity tumor cell clusters in malignant peritoneal mesothelioma
Journal of Surgical Oncology 2024 August 24 [Link] Yan-Dong Su, Ru Ma, Yu-Bin Fu, He-Liang Wu, Xin-Li Liang, Yi-Tong Liu, Yang Yu, Zhi-Ran Yang, Yan Li Abstract Background: To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor-like cell clusters (PTC) drug sensitivity test. Methods: PTC were cultured…
Read MoreDrug sensitivity tumor cell clusters in malignant peritoneal mesothelioma
Journal of Surgical Oncology 2024 August 25 [Link] Yan-Dong Su, Ru Ma, Yu-Bin Fu, He-Liang Wu, Xin-Li Liang, Yi-Tong Liu, Yang Yu, Zhi-Ran Yang, Yan Li Abstract Background: To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor-like cell clusters (PTC) drug sensitivity test. Methods: PTC were cultured…
Read MoreStemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei
International Journal of Cancer 2024 August 15 [Link] Nayana Lazzari, Giulia Rigotto, Barbara Montini, Paola Del Bianco, Elena Moretto, Federica Palladino, Rocco Cappellesso, Marco Tonello, Carola Cenzi, Antonio Scapinello Maria Assunta Piano, Carlo Riccardo Rossi, Piero Dalerba, Pierluigi Pilati, Antonio Sommariva, Maria Luisa Calabrò Abstract Intrabdominal dissemination of malignant mesothelioma (MM) and pseudomyxoma peritonei (PMP)…
Read MoreComparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience
Journal of the College of Physicians and Surgeons 2024 August [Link] Yasin Sezgin, Ogur Karhan, Serdar Ileri, Senar Ebinc, Sezai Tunc, Zuhat Urakci Abstract Objective: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapy…
Read More